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Available online 19 November 2015The advancement of next generation sequencing (NGS) has made
possible large scale tumor molecule proﬁling and thus, the molecular
classiﬁcation of tumor subtypes. The Cancer Genome Atlas (TCGA) has
been successful in publishing many important discoveries elucidating
the mutation landscape, including the recent Cell article (Cancer
Genome Atlas Research Network. Electronic address, s.c.m.o. and
Cancer Genome Atlas Research, N., 2015), where at least seven molecu-
lar subtypes were proposed for prostate tumors. Although it is well
known that both incidence and mortality are substantially higher in
men of African ancestry, most prostate tumor molecular proﬁling
studies have been conducted on men of European ancestry (Baca
et al., 2013; Robinson et al., 2015). In this issue of EBioMedicine,
Petrovics et al. (2015) reported distinctly different spectrums of geno-
mic alterations in prostate tumors between African American (AA)
and Caucasian American (CA) men. Such in-depth research focusing
on racial differences adds more insights into our understanding of mo-
lecular carcinogenesis and tumor heterogeneity for prostate cancer.
The key ﬁnding of this current study by Petrovics et al. is the novel
prevalent deletion of 3q13.31 locus centering on LSAMP gene in AA pros-
tate cancer tumors, especially those likely to lead to recurrence or pro-
gression. Such a mutation could potentially be used as a valuable
treatment target and/or prognostic biomarker in clinical setting with fur-
ther conﬁrmation and studies of its role in prostate tumor biology. Local
ancestry analysis in this genomic region is also likely to advance our un-
derstanding on the underlyingmechanism leading to differential somatic
alterations between prostate cancer patients of European and African an-
cestry. In addition, signiﬁcantly higher frequency of inter-chromosome
rearrangements, a phenomenon called “chromoplexy” (Baca et al.,
2013), was also observed in prostate tumors from AA as compared to
CA men in this study. Higher prevalence of the signature deletion of
LSAMP gene and inter-chromosome rearrangements may explain some
of the observed health disparity of prostate cancer in AA population.om.2015.10.028.
. This is an open access article underThe study by Petrovics et al. provided a paradigm for studying other
cancer types with large racial or ethnic difference in prevalence and/or
disease severity. Along this line, a recent study based on TCGA data
alone was conducted in comparing the genomic landscape of breast
cancer between AA and CA women and suggested more aggressive
tumor biology in AA than CA (Keenan et al., 2015). One notable aspect
of Petrovics et al.'s ﬁndings is that recurrent prostate cancer driver mu-
tations, such as those involved in either PTEN or ERG genes, commonly
observed in CA men, are less frequent in AA men. Such information
may be useful in developing and applying the targeted therapeutics
for patients with different ethnic background. Remarkably lower fre-
quencyof PTEN loss in AAprostate cancer patientswouldmake the ther-
apeutics targeting loss of PTEN less likely to be successful in treating AA
patients with prostate cancer.
Tumor genomic proﬁling andmolecular subtyping is critically impli-
cated in the new Precision Medicine Initiative (PMI) called upon by
President Obama, however, investigations of genetic predisposition
and population risk stratiﬁcation are equally important. The new Preci-
sion Medicine Initiative (PMI) speciﬁcally calls for the enrollment
of under studied populations including AA. The multiethnic cohort
(MEC) study has suggested that the underlying genetics play a greater
role in explaining racial/ethnic differences in prostate cancer risk than
lifestyle factors (Park et al., 2015). For the germline susceptibility, both
difference and commonalitywere observed and highlighted by assessing
the genetic risk loci originally discovered in CA in the AA population
(Haiman et al., 2011). Moving forward, the integration of both germline
(for susceptibility) and somatic (for progression) genomic datawill open
up a newvenue in searching for germline-somatic continuums in under-
standing of tumorigenesis and development of personalized cancer
medicine (Pujana, 2014; Feigelson et al., 2014).
Petrovics et al. demonstrated that the statistical power can be im-
proved by combining and integrating different data types including
whole genome sequencing (WGS), FISH assays and SNP array data.
Despite the initial discovery was based on only 7 CA and 7 AA tumor/
normal pairs of WGS data, the ﬁndings of LSAMP deletion were further
replicated in 1) TCGA SNP array data for 279 CA and 41 AA patients;
and 2) FISH assay data for 59 CA and 42 AA. Even larger sample size,
especially for the discovery phase, could possibly lead to additional
novel ﬁndings highlighting differences in prostate tumors between CA
and AA patients.
More comprehensive and systematic research is needed in order to
further advance our understanding of the tumor heterogeneity among
worldwide populations for prostate and other cancers. As NGS becomesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1851Z. Wang / EBioMedicine 2 (2015) 1850–1851more routine in clinical and research laboratories, somatic lesions iden-
tiﬁed by sequencing the cancer genomewill certainly improve the per-
sonalized treatment and clinical management for the cancer patient. In
themeantime, the reportable pathogenic germlinemutations identiﬁed
by sequencing the paired normal tissue or blood samples could prompt
the genetic screening of the family and relatives for cancer or disease
predisposition and subsequent prevention to realize the promise of
precision medicine in the very near future.Disclosure
The author declared no conﬂicts of interest.References
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